Concise Prescribing Info
Acute & chronic treatment of the signs & symptoms of OA & RA. Ankylosing spondylitis. Acute gouty arthritis. Relief of chronic musculo-skeletal pain including chronic low back pain; acute pain including dental surgery. Primary dysmenorrhea; moderate to severe post-op pain associated w/ abdominal gynecological surgery.
Dosage/Direction for Use
OA Recommended dose: 60 mg once daily. RA, ankylosing spondylitis 90 mg once daily. Acute gouty arthritis 120 mg once daily. Chronic musculoskeletal pain including chronic low back pain 90 or 120 mg once daily. Max: 4 wk. Acute pain 90 mg. Max: 8 days. Post-op dental pain 90 mg. Max: 3 days.  Primary dysmenorrhea 120 mg once daily. Max: 8 days. Post-op abdominal gynecological pain 90 or 120 mg once daily. Mild hepatic impairment (Child-Pugh score 5-6) Max: 60 mg daily. Moderate hepatic impairment (Child-Pugh score 7-9) Max: 60 mg on alternate days or 30 mg once daily.
May be taken with or without food.
Hypersensitivity. Patients w/ moderate to severe heart failure (NYHA II-IV), renal impairment (CrCl <30 mL/min), ischemic heart disease, peripheral arterial disease or cerebrovascular disease, severe hepatic impairment (Child-Pugh score of 10 or more); HTN whose BP is not controlled; active GI ulceration or bleeding, inflammatory bowel disease.
Special Precautions
Risk of thrombotic events. Do not administer to patients whose BP is persistently >140/90 mmHg & inadequately controlled. Control BP prior to starting treatment & monitor for 2 wk regularly, thereafter. Avoid in patients w/ hepatic impairment; avoid in severe liver disease (Child-Pugh ≥10); active GI ulceration or bleeding; renal impairment. Monitor renal function. Avoid in patients w/ eGFR <30 mL/min/1.73 m2. Pregnancy & lactation.
Adverse Reactions
Discomfort, nausea, diarrhoea, bleeding, ulceration; hypersensitivity (rash, angioedema, bronchospasm); headache, vertigo, dizziness, depression, drowsiness, insomnia; photosensitivity; haematuria, renal failure; HTN, CHF.
Drug Interactions
May decrease antihypertensive effect & increase risk of nephrotoxicity w/ ACE inhibitors &/or AIIA. Increased plasma conc w/ azole antifungals eg, fluconazole, ketoconazole). May increase risk of GI bleeding w/ oral corticosteroids eg, prednisolone, or antiplatelet therapy (eg, clopidogrel, prasugrel). May increase risk of anticoagulant-induced bleeding w/ warfarin. May impair effect of β-blockers. May increase nephrotoxicity w/ cyclosporin & tacrolimus. Decrease effect of diuretics (thiazides, K-sparing diuretics, loop diuretics). May increase plasma levels of lithium. May increase risk of methotrexate toxicity.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.
Biocoxib FC tab 120 mg
3 × 10's;5 × 5's
Biocoxib FC tab 60 mg
3 × 10's
Biocoxib FC tab 90 mg
3 × 10's;5 × 5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in